专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060261043A1 Apparatus and method for circuit operation definition 有权
公开(公告)号：US20060261043A1
公开(公告)日：2006-11-23
申请号：US11363787
申请日：2006-02-27
申请人： Martin Betz , Lokesh Johri , Rajesh Jain , Theodore Lundquist , Tamal Basu , Saurabh Gupta , Jagadish Narayana Gade
发明人： Martin Betz , Lokesh Johri , Rajesh Jain , Theodore Lundquist , Tamal Basu , Saurabh Gupta , Jagadish Narayana Gade
IPC分类号： H01H33/14
CPC分类号： G06F17/5068
摘要： A method and apparatus for defining a circuit operation, such as a charged particle beam operation to perform a circuit edit and define a probe point. Circuit operation definition is performed in a front-end environment with access to integrated circuit computer aided design tools providing logic level and layout level information concerning the integrated circuit. The front-end environment incorporates circuit operation optimization methods to identify optimal locations for a circuit operation. A back-end environment, such as a charged particle tool computing platform, is adapted to receive one or more files, which may include a truncated layout file with circuit operation location information, for use in further defining a circuit operation and/or performing the circuit operation.

2. 发明授权

US07530034B2 Apparatus and method for circuit operation definition 有权
标题翻译：电路操作定义的装置和方法
公开(公告)号：US07530034B2
公开(公告)日：2009-05-05
申请号：US11363787
申请日：2006-02-27
申请人： Martin Betz , Lokesh Johri , Rajesh Jain , Theodore R. Lundquist , Tamal Basu , Saurabh Gupta , Jagadish Narayana Gade
发明人： Martin Betz , Lokesh Johri , Rajesh Jain , Theodore R. Lundquist , Tamal Basu , Saurabh Gupta , Jagadish Narayana Gade
IPC分类号： G06F17/50
CPC分类号： G06F17/5068
摘要： A method and apparatus for defining a circuit operation, such as a charged particle beam operation to perform a circuit edit and define a probe point. Circuit operation definition is performed in a front-end environment with access to integrated circuit computer aided design tools providing logic level and layout level information concerning the integrated circuit. The front-end environment incorporates circuit operation optimization methods to identify optimal locations for a circuit operation. A back-end environment, such as a charged particle tool computing platform, is adapted to receive one or more files, which may include a truncated layout file with circuit operation location information, for use in further defining a circuit operation and/or performing the circuit operation.
摘要翻译：一种用于定义电路操作的方法和装置，例如带电粒子束操作以执行电路编辑并定义探测点。电路操作定义在前端环境中执行，可访问集成电路计算机辅助设计工具，提供有关集成电路的逻辑电平和布局级信息。前端环境包含电路操作优化方法，以确定电路操作的最佳位置。诸如带电粒子工具计算平台的后端环境适于接收一个或多个文件，其可以包括具有电路操作位置信息的截断的布局文件，以用于进一步定义电路操作和/或执行电路操作。

3. 发明申请

US20070293052A1 APPARATUS AND METHOD FOR OPTICAL INTERFERENCE FRINGE BASED INTEGRATED CIRCUIT PROCESSING 有权
标题翻译：基于光干扰法的基于集成电路处理的装置和方法
公开(公告)号：US20070293052A1
公开(公告)日：2007-12-20
申请号：US11754466
申请日：2007-05-29
申请人： Erwan Le Roy , Chun-Cheng Tsao , Theodore Lundquist , Rajesh Jain
发明人： Erwan Le Roy , Chun-Cheng Tsao , Theodore Lundquist , Rajesh Jain
IPC分类号： H01L21/302
CPC分类号： H01L21/3065 , H01J37/228 , H01J37/3056 , H01J2237/2482 , H01J2237/30466 , H01J2237/31749 , H01L22/12 , H01L22/26
摘要： An apparatus and method for processing an integrated circuit employing optical interference fringes. During processing, one or more wavelength lights are directed on the integrated circuit and based upon the detection of interference fringes and characteristics of the same, further processing may be controlled. One implementation involves charged particle beam processing of an integrated circuit as function of detection and/or characteristics of interference fringes. A charged particle beam trench milling operation is performed in or on the substrate of an integrated circuit. Light is directed on the floor of the trench. Interference fringes may be formed from the constructive or destructive interference between the light reflected from the floor and the light from the circuit structures. Resulting fringes will be a function, in part, of the thickness and/or profile of the trench floor. Milling may be controlled as a function of the detected fringe patterns.
摘要翻译：一种使用光学干涉条纹处理集成电路的装置和方法。在处理期间，一个或多个波长的光被引导到集成电路上，并且基于干涉条纹和其特性的检测，可以控制进一步的处理。一种实施方案涉及集成电路的带电粒子束处理，作为干涉条纹的检测和/或特征的函数。在集成电路的衬底中或其上执行带电粒子束沟槽铣削操作。光线指向沟槽的地板。干涉条纹可以由从地板反射的光与来自电路结构的光之间的建构性或破坏性干扰形成。所产生的条纹将部分地是沟槽地板的厚度和/或轮廓的函数。作为检测到的条纹图案的函数可以控制铣削。

4. 发明授权

US09642808B2 Extended release compositions comprising mycophenolate sodium and processes thereof 有权
公开(公告)号：US09642808B2
公开(公告)日：2017-05-09
申请号：US12672180
申请日：2008-08-11
申请人： Rajesh Jain , Sukhjeet Singh , Sampath Kumar Devarajan
发明人： Rajesh Jain , Sukhjeet Singh , Sampath Kumar Devarajan
IPC分类号： A61K31/343 , A61K9/20 , A61K9/28 , A61K31/365
CPC分类号： A61K9/2077 , A61K9/2013 , A61K9/2846 , A61K31/365
摘要： Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases).

5. 发明申请

US20130302383A1 LIQUID ORAL COMPOSITION OF LANTHANUM SALTS 有权
标题翻译：海盐的液体口服成分
公开(公告)号：US20130302383A1
公开(公告)日：2013-11-14
申请号：US13979997
申请日：2012-01-17
申请人： Rajesh Jain , Sarabjit Singh , Paramjit Singh , Pirthi Pal Singh
发明人： Rajesh Jain , Sarabjit Singh , Paramjit Singh , Pirthi Pal Singh
IPC分类号： A61K9/00 , A61K33/24
CPC分类号： A61K9/0053 , A61K9/0095 , A61K33/24 , A61K47/02 , A61K47/14 , A61K47/26 , A61K47/38
摘要： The present invention relates to liquid oral pharmaceutical compositions of lanthanum and its pharmaceutically acceptable salts thereof. The present invention further relates to preparation of liquid oral pharmaceutical compositions of lanthanum and its salts and also provides use of such compositions in treating hyperphosphatemia in patients.
摘要翻译：本发明涉及镧的液体口服药物组合物及其药学上可接受的盐。本发明还涉及镧及其盐的液体口服药物组合物的制备，并且还提供了这些组合物在患者中治疗高磷血症的用途。

6. 发明授权

US08551451B2 Combination vaccine with acellular pertussis 有权
标题翻译：具有无细胞百日咳组合疫苗
公开(公告)号：US08551451B2
公开(公告)日：2013-10-08
申请号：US13125708
申请日：2009-10-23
申请人： Rajesh Jain , Sukhjeet Singh , Lavit Jambu
发明人： Rajesh Jain , Sukhjeet Singh , Lavit Jambu
IPC分类号： A61K49/00 , A61K39/00 , A61K39/02
CPC分类号： A61K39/05 , A61K39/0018 , A61K39/08 , A61K39/099 , A61K39/102 , A61K39/12 , A61K39/13 , A61K39/292 , A61K2039/5252 , A61K2039/55505 , A61K2039/70 , C12N2730/10134 , C12N2770/32634 , Y02A50/466
摘要： The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by Haemophilus influenzae and polio viruses. The present invention also relates to inclusion of antigens for protection against infections caused Hepatitis virus and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.
摘要翻译：本发明涉及包含抗原混合物的组合疫苗，用于防止诸如白喉，破伤风，无细胞百日咳和由流感嗜血杆菌和脊髓灰质炎病毒引起的感染。本发明还涉及包含用于防止引起的肝炎病毒和其他病原体的感染的抗原，使得疫苗的施用可以同时针对多于一种的病原体免疫受试者。本发明特别涉及包含上述抗原的完全液体稳定的组合疫苗及其制备方法。

7. 发明申请

US20130253029A1 NOVEL BICYCLIC COMPOUNDS 有权
标题翻译：新型双环化合物
公开(公告)号：US20130253029A1
公开(公告)日：2013-09-26
申请号：US13876757
申请日：2011-09-27
申请人： Rajesh Jain , Sanjay Trehan , Jagattaran Das , Nishan Singh , Sudhir Kumar Sharma
发明人： Rajesh Jain , Sanjay Trehan , Jagattaran Das , Nishan Singh , Sudhir Kumar Sharma
IPC分类号： C07D209/52 , A61K45/06 , A61K31/403
CPC分类号： C07D209/52 , A61K31/403 , A61K45/06
摘要： The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).
摘要翻译：本发明涉及式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂化物。本发明还涉及合成式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。本发明还提供包含式I化合物的药物组合物和治疗或预防中枢和/或周围神经系统的一种或多种病症的方法，优选通过调节神经和/或精神病学靶标（GPCR和/或非GPCR）。

8. 发明申请

US20110223249A1 EXTENDED RELEASE COMPOSITIONS COMPRISING MYCOPHENOLATE SODIUM AND PROCESSES THEREOF 有权
标题翻译：包含MYCOPHENOLATE SODIUM的扩展性释放组合物及其过程
公开(公告)号：US20110223249A1
公开(公告)日：2011-09-15
申请号：US12672180
申请日：2008-08-11
申请人： Rajesh Jain , Sukhjeet Singh , Sampath Kumar Devarajan
发明人： Rajesh Jain , Sukhjeet Singh , Sampath Kumar Devarajan
IPC分类号： A61K31/343 , A61K9/00 , A61K9/24 , A61K9/28 , A61P35/00 , A61P11/00 , A61P25/00 , A61P9/00 , A61P29/00 , A61P31/00
CPC分类号： A61K9/2077 , A61K9/2013 , A61K9/2846 , A61K31/365
摘要： Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases).
摘要翻译：包含霉酚酸钠作为活性剂的延长释放药物组合物，其中当进行体外溶出研究时，所述组合物表现出特征性释放曲线，并且其中所述霉酚酸钠以持续的方式在体内以这种方式长时间释放提供了大大减轻或至少降低引起任何相关胃肠道副作用而不损害所述活性剂的生物利用度的机会的量。本发明还提供了使用这种剂型的剂型组合物和预防和/或治疗方法的制备方法。本发明的组合物可用于治疗，例如预防，改善和/或治疗指示的疾病/病症，特别是用于治疗或预防器官，组织或细胞同种异体移植物或异种移植物排斥反应的免疫抑制剂，例如，移植后，或免疫介导的疾病（自身免疫性疾病）的管理。

9. 发明申请

US20100234288A1 SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION ON THE BASIS OF RELEASE SYSTEM COMPRISING AN ACID-SOLUBLE POLYMER AND A pH-DEPENDENT POLYMER 审中-公开
标题翻译：基于包含可溶性聚合物和pH依赖性聚合物的释放系统的基础上的持续释放药物组合物
公开(公告)号：US20100234288A1
公开(公告)日：2010-09-16
申请号：US12294482
申请日：2007-03-19
申请人： Rajesh Jain , Kour Chand Jindal , Sampath Kumar Devarajan
发明人： Rajesh Jain , Kour Chand Jindal , Sampath Kumar Devarajan
IPC分类号： A61K38/16 , A61K31/7088 , A61K31/437 , A61K31/5513 , A61K31/5415 , A61K31/5517 , A61K31/554 , A61K31/496 , A61P25/18
CPC分类号： A61K9/2853
摘要： Sustained release pharmaceutical composition comprising at least one poorly soluble active agent(s), at least one solubilizer, a release rate controlling polymer system consisting of an acid-soluble polymer and a pH-dependent polymer, and optionally other pharmaceutically acceptable excipients. The present invention also describes a process for preparation of such compositions and method of using such compositions. The sustained release compositions are useful in providing therapeutically effective levels of active agent(s) for extended periods of time.
摘要翻译：包含至少一种不易溶解的活性剂，至少一种增溶剂，由酸溶性聚合物和pH依赖聚合物组成的释放速率控制聚合物体系以及任选其它药学上可接受的赋形剂的缓释药物组合物。本发明还描述了这种组合物的制备方法和使用这种组合物的方法。持续释放组合物可用于在长时间内提供治疗有效水平的活性剂。

10. 发明申请

US20100204333A1 Novel Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor 审中-公开
标题翻译：新型药物改性释放剂型环氧合酶抑制剂
公开(公告)号：US20100204333A1
公开(公告)日：2010-08-12
申请号：US11988860
申请日：2006-07-19
申请人： Rajesh Jain , Kour Chand Jindal , Sukhjeet Singh , Munish Talwar
发明人： Rajesh Jain , Kour Chand Jindal , Sukhjeet Singh , Munish Talwar
IPC分类号： A61K31/18 , A61P25/00 , A61P25/06
CPC分类号： A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/209 , A61K9/4808 , A61K9/4858 , A61K9/4866 , A61K9/5084 , A61K31/18 , A61K31/192 , A61K31/415
摘要： Pharmaceutical modified release dosage form comprising at least one cyclooxygenase enzyme inhibitor or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof as active agent, with a pharmaceutically acceptable carrier for controlling the release of the cyclooxygenase enzyme inhibitor is provided. The dosage form preferably provides a release of not more than about 60% of the cyclooxygenase enzyme inhibitor in 1 hour and not less than about 75% of the cyclooxygenase enzyme inhibitor after 12 hours when tested in accordance with the dissolution method (I) described herein employing Distilled water with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (II) described herein employing pH 7.0 Phosphate buffer with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (III) described herein employing 0.001 N Hydrochloric acid with 1.0% Sodium lauryl sulphate as dissolution medium. Further, the pharmaceutical composition of the present invention when tested in a group of healthy humans preferably achieves a mean peak plasma concentration (Cmax) after at least about 1 hour of administration of the dosage form. The present invention also provides process of preparing such dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form.
摘要翻译：提供了包含至少一种环加氧酶酶抑制剂或其药学上可接受的盐，酯，前药，溶剂化物或其衍生物作为活性剂的药物改性释放剂型，以及用于控制环加氧酶抑制剂释放的药学上可接受的载体。根据本文所述的溶解方法（I）测试时，剂型优选在12小时后提供不超过约60％的环氧合酶抑制剂的释放量，并且不少于约75％的环氧合酶抑制剂。使用2.0％十二烷基硫酸钠作为溶解介质的蒸馏水或根据本文所述的溶解方法（II），使用pH 7.0的磷酸盐缓冲液，含有2.0％十二烷基硫酸钠作为溶解介质，或根据溶解方法（III）本文使用0.001N盐酸与1.0％十二烷基硫酸钠作为溶解介质。此外，当在一组健康人中测试时，本发明的药物组合物优选在施用剂型至少约1小时后达到平均峰值血浆浓度（C max）。本发明还提供了制备这种剂型组合物的方法和使用这种剂型的预防和/或治疗方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式